Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
acknowledged, ADA, adequacy, AE, anaplastic, Anderson, Ansam, assed, assumption, atezolizumab, Atlantic, ATM, avdoralimab, avelumab, awardee, BA, Bangladesh, Belgium, Benchmark, Berlin, BID, Biden, Bio, Biotie, blacklist, breast, bronbelasting, carcinoma, career, carryforward, CDS, Centre, cetuximab, cGCP, chosen, cisplatin, clot, CMC, cobimetinib, collateral, Concession, constitutionality, contractor, Corona, cscc, curable, curative, dehydrogenase, died, distance, distant, dramatically, EGFR, EIR, Eli, endorsed, epidermal, Ernst, exoSTING, feedback, fluidity, foreach, Forest, futility, Georgetown, GlaxoSmithKline, Hospitalier, Imcyse, incl, Indonesia, inflection, interposed, intubated, intubation, invoiced, invoicing, Iveric, Jordan, JP, Kettering, kinase, Korinna, Kuebler, lactate, laherparepvec, Landeskliniken, leakage, lenvatinib, LIBTAYO, Lilly, Lily, LTIP, lymph, lymphocytopenia, MD, Medtronic, Memorial, mepolizumab, MI, Mild, misallocation, monotherapy, NDA, neck, nested, nivolumab, node, Northern, Nucala, obstructive, Oyj, panitumumab, parliament, pattern, paused, PDUFA, PF, Pfizer, photoimmunotherapy, Pilz, platform, Poland, premium, presidential, radiation, Rakuten, ravulizumab, Raymond, reaction, recession, recurrence, recurrent, respiratory, resume, resumed, Salzburger, SAVE, SCC, Scibase, sector, SIC, Sichuan, simplify, solid, Sotio, Southern, SPA, Spain, story, stricter, sun, SVB, Taapken, talimogene, telecommunication, thyroid, tube, turnaround, unavoidable, unbilled, unchanged, upadacitinib, variant, ventilator, Verlustvortrag, vilobelimab, Wagner, Wake, Web, Young, Zhejiang, Zwick
Removed:
Achillion, Arnd, Avery, Biostructure, Cadillac, cancelable, CF, Christ, close, comfort, correspondingly, deed, Dennison, dilutive, dissolution, East, EleGene, excise, excluded, exhibited, exit, Fireman, Frankfurt, indefinitely, leasehold, legally, likewise, loosen, mandate, Moody, notarial, NovImmune, Ophthotech, Poor, Port, Probiodrug, rated, repealing, subscribed, Tabular, tranche, Trump, XBiotech
Filing tables
Filing exhibits
IFRX similar filings
Filing view
External links
Exhibit 15.2
Consent of Independent Registered Public Accounting Firm
The Board of Directors of InflaRx N.V.:
We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333-221656 and No. 333-240185) and on Form F-3 (No. 333-239759) of InflaRx N.V. of our report dated April 28, 2020, with respect to the consolidated statement of financial position of InflaRx N.V. as of December 31, 2019, and the related consolidated statements of operations and comprehensive loss, changes in shareholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2019, and the related notes, which report appears in the December 31, 2020 annual report on Form 20-F of InflaRx N.V.
/s/ KPMG AG Wirtschaftsprüfungsgesellschaft
Leipzig, Germany
March 25, 2021